

Testosterone levels in nmol/L												
Paper	Comment	Modality	Mean	Median	SD	RangeL	RangeH	95%L	95%H	IQRL	IQRH	
Control	Yamashita et al. 2009	age 41-50	LC-MS/MS	14,0		3,3						
	Yamashita et al. 2009	age 51-60	LC-MS/MS	15,5		6,1						
	Yamashita et al. 2009	age 61-70	LC-MS/MS	17,6		7,0						
	Yamashita et al. 2009	age 71-85	LC-MS/MS	12,8		6,2						
	Schenk et al. 2016		CL immunoassay	13,3					13,0	13,5		
	Tsilidis et al. 2015		Radioimmunoassay	15,9					15,4	16,4		
	Stanczyk et al. 2013		Radioimmunoassay	17,7								
	Meyer et al. 2012		Radioimmunoassay	17,6		8,5						
	Wirén et al. 2007		Radioimmunoassay	21,8		8,4						
	Mondul et al. 2010		CL immunoassay	17,7					17,1	18,4		
	Daniels et al. 2010		GC-MS	14,3		5,4						
	Grosman et al. 2010		Radioimmunoassay	14,6		5,9						
	Crawford et al. 2007		CL immunoassay	14,4	13,2	6,6						
	Hammond et al. 1978		Radioimmunoassay				20,0	25,0				
	St Sauver et al. 2011		CL immunoassay	11,7								
	Dorgan et al. 1998		Radioimmunoassay		21,6						16,7	24,5
	Rarter et al. 1995 and Parsons et al. 2005		Radioimmunoassay		15,2						12,9	18,7
	Chen et al. 2003		Radioimmunoassay		14,2						11,3	17,8
	Hsing and Comstock 1993 and Comstock et al. 1993		Radioimmunoassay		13,7						10,0	20,3
	Travis et al. 2007		Radioimmunoassay		16,1						12,2	20,7
	Heikkila et al. 1999		Radioimmunoassay		23,5						18,5	29,9
	Stattin et al. 2004	HHS (NBSWG)	Radioimmunoassay		20,2						16,2	24,5
	Platz et al. 2005		Radioimmunoassay		16,0						12,5	20,2
	Ozasa et al. 2004		Radioimmunoassay		15,5						12,7	19,5
	Vatten et al. 1997		Radioimmunoassay		18,1						15,3	24,0
	Stattin et al. 2004		Radioimmunoassay		23,1						18,1	29,1
	Nomura et al. 1988 and Nomura et al. 1996		Radioimmunoassay		17,6						13,4	23,0
	Severi et al. 2006		CL immunoassay		15,8						12,4	19,6
Stattin et al. 2004	NSHDC	CL immunoassay		21,7						16,4	28,3	
Gann et al. 1996		Radioimmunoassay		16,2						12,6	20,3	
Oliver et al. 2004		Radioimmunoassay		13,8						10,6	17,5	
Barrett-Conner et al. 1990		Radioimmunoassay		10,4						8,7	13,3	

BPH	Grosman et al. 2010		Radioimmunoassay	16,64		5,2			
	Heracek et al. 2007		Radioimmunoassay	15,83	14,4	7,59			
	Hammond et al. 1978		Radioimmunoassay				17,5	37,5	

Prostate	Hammond et al. 1997		Radioimmunoassay				2,1	34,7			
	Wirén et al. 2007		Radioimmunoassay	21,4		9,3					
	Daniels et al. 2010		GC-MS	14,4		5,3					
	Grosman et al. 2010		Radioimmunoassay	16,6		5,9					
	Heracek et al. 2007		Radioimmunoassay	14,8	13,6	6,9					
	Hammond et al. 1978		Radioimmunoassay				10,0	32,5			
	Taplin et al. 2014	Group 1	LC-MS/MS	14,9			0,0	41,1			
	Taplin et al. 2014	Group 2	LC-MS/MS	14,8			4,9	26,4			
	Miyoshi et al. 2014		LC-MS/MS		12,3				12,1	13,5	
	Mostaghel et al. 2014		LC-MS/MS	12,8		3,9					
	Røhl and Beuke 1992		Radioimmunoassay	12,5							
	Hara et al. 2013		CL immunoassay	16,0		5,1					
	Hara et al. 2012		CL immunoassay	16,1		5,0					
	Salonia et al. 2013 (PMID: 23283410)		CL immunoassay		15,3		0,0	36,8			
	Porcaro et al. 2013		CL immunoassay	16,7		6,8					
	Porcaro et al. 2012		CL immunoassay	16,3		6,7					
	Salonia et al. 2012		CL immunoassay	14,9			0,1	47,2			
	Ishizaki et al. 2012		CL immunoassay	16,1		5,2					
	Dorgan et al. 1998		Radioimmunoassay		20,8					15,8	24,3
	Rarter et al. 1995 and Parsons et al. 2005		Radioimmunoassay		15,3					12,5	17,9
	Chen et al. 2003		Radioimmunoassay		14,0					10,8	17,5
	Hsing and Comstock 1993 and Comstock et al. 1993		Radioimmunoassay		14,3					12,3	18,5
	Travis et al. 2007		Radioimmunoassay		16,2					11,8	21,2
	Heikkila et al. 1999		Radioimmunoassay		23,9					17,9	31,0
Stattin et al. 2004	HHS (NBSWG)	CL immunoassay		20,4					16,6	24,0	
Platz et al. 2005		Radioimmunoassay		16,1					12,4	20,5	
Ozasa et al. 2004		Radioimmunoassay		16,4					13,4	19,5	
Vatten et al. 1997		Radioimmunoassay		18,2					14,5	24,2	
Stattin et al. 2004		Radioimmunoassay		22,1					17,6	27,1	
Nomura et al. 1988 and Nomura et al. 1996		Radioimmunoassay		17,4					12,9	23,6	

	Severi et al. 2006		Radioimmunoassay		15,5				12,9	18,9
	Stattin et al. 2004	NSHDC	CL immunoassay		21,6				17,1	27,5
	Gann et al. 1996		Radioimmunoassay		16,7				13,2	20,4
	Oliver et al. 2004		Radioimmunoassay		14,3				11,5	18,7
	Barrett-Conner et al. 1990		Radioimmunoassay		10,9				7,7	13,6
	Nakai et al. 2015	flutamide	Radioimmunoassay		19,78		6,94	33,66		
	Nakai et al. 2015	biclutamide	unknown		15,62		9,72	26,72		
	Qin X et al. 2013	mPC naive	Radioimmunoassay	14,1					12,0	16,2

ADT	Taplin et al. 2014		LC-MS/MS	0,60			0,02	2,12		
	Mostaghel et al. 2014	ADT + bicalutamide	LC-MS/MS	0,62		0,36				
	Mostaghel et al. 2014	ADT + dutasteride	LC-MS/MS	0,94		0,85				
	Mostaghel et al. 2014	CAB	LC-MS/MS	0,46		0,15				
	Mostaghel et al. 2014	CAB + ketoconazol	LC-MS/MS	0,33		0,22				
	Røhl and Beuke 1992	orchiectomy (1m)	Radioimmunoassay	0,73						
	Røhl and Beuke 1992	orchiectomy (3m)	Radioimmunoassay	0,67						
	Røhl and Beuke 1992	orchiectomy (6m)	Radioimmunoassay	0,56						
	Røhl and Beuke 1992	orchiectomy (12m)	Radioimmunoassay	0,55						
	Hara et al. 2013		CL immunoassay	0,52		0,35				
	Hara et al. 2012		CL immunoassay	0,50		0,30				
	van der Sluis et al. 2012	orchiectomy	LC-MS/MS		0,32		0,10	1,00		
	van der Sluis et al. 2012		LC-MS/MS		0,14		0,10	0,70		
	Ishizaki et al. 2012		CL immunoassay	0,50		0,40				
	Qin X et al. 2013	ADT-sensitive	Radioimmunoassay	0,52					0,38	0,66
Qin X et al. 2013	ADT-nonsensitive	Radioimmunoassay	0,38					0,17	0,52	

CRPC	Qin X et al. 2013		Radioimmunoassay	0,312					0,104	0,521
	Ryan et al. 2014	abiraterone + prednisone	LC-MS/MS	0,205			0,010	0,611		
	Ryan et al. 2014	prednisone (baseline)	LC-MS/MS	0,194			0,010	0,586		
	Ryan et al. 2014	prednisone (12w)	LC-MS/MS	0,101		0,017				
	Attard et al. 2008		LC-MS/MS		0,243		0,035	1,180		

Abiraterone	Taplin et al. 2014	ADT + abiraterone (12w)	LC-MS/MS	0,232			0,017	0,493		
	Kim W et al. 2014	Responder	LC-MS/MS		0,104					
	Kim W et al. 2014	Non-responder	LC-MS/MS		0,104					
	McKay et al. 2017	abiraterone low (+dutasteride)	LC-MS/MS		0,014					0,010 0,024
	McKay et al. 2017	abiraterone high (+dutasteride)	LC-MS/MS		0,017					0,010 0,021
	Ryan et al. 2014	abiraterone + prednisone (12w)	LC-MS/MS	0,017		0,005				
	Attard et al. 2008		LC-MS/MS		0,035		0,035	0,035		

Dihydrotestosterone (DHT) levels in nmol/L											
Paper	Comment	Modality	Mean	Median	SD	RangeL	RangeH	95%L	95%H	IQRL	IQRH

Control	Yamashita et al. 2009	age 41-50	LC-MS/MS	1,204		0,2752					
	Yamashita et al. 2009	age 51-60	LC-MS/MS	1,65		0,52					
	Yamashita et al. 2009	age 61-70	LC-MS/MS	2,00		1,00					
	Yamashita et al. 2009	age 71-85	LC-MS/MS	1,82		1,10					
	Dorgan et al. 1998		Radioimmunoassay		1,89					1,48	2,27
	Hsing and Comstock 1993 and Comstock et al. 1993		Radioimmunoassay		1,64					1,23	2,27
	Platz et al. 2005		Radioimmunoassay		1,34					0,91	1,81
	Vatten et al. 1997		Radioimmunoassay		1,58					1,21	2,04
	Nomura et al. 1988 and Nomura et al. 1996		Radioimmunoassay		1,86					1,35	2,52
	Gann et al. 1996		Radioimmunoassay		1,24					0,79	1,79
	Barrett-Conner et al. 1990		Radioimmunoassay		1,43					1,10	1,87
	Stanczyk et al. 2013		Radioimmunoassay	1,72		0,17					
	Hammond et al. 1978		Radioimmunoassay				2,00	2,10			
Trifiro et al. 2010		Radioimmunoassay	1,44		0,52						

BPH	Heracek et al. 2007		Radioimmunoassay	2,12	2,04	0,70					
	Hammond et al. 1978		Radioimmunoassay				2,00	3,50			
	Parsons et al. 2010		Radioimmunoassay	1,65		0,60					
	Clark et al. 2004	dutasteride	GC-MS	0,03		0,03					

Prostate	Dorgan et al. 1998		Radioimmunoassay		1,85				1,48	2,17
	Hsing and Comstock 1993 and Comstock et al. 1993		Radioimmunoassay		1,60				1,23	2,27
	Platz et al. 2005		Radioimmunoassay		1,34				0,81	1,90
	Vatten et al. 1997		Radioimmunoassay		1,60				1,19	2,08
	Nomura et al. 1988 and Nomura et al. 1996		Radioimmunoassay		1,80				1,29	2,52
	Gann et al. 1996		Radioimmunoassay		1,16				0,79	1,76
	Barrett-Conner et al. 1990		Radioimmunoassay		1,53				0,98	1,98
	Muller et al. 2012	Gleason 2-6	LC-MS/MS		1,20		0,20	9,80	0,80	1,60
	Muller et al. 2012	Gleason 7	LC-MS/MS		1,10		0,10	7,10	0,80	1,60
	Muller et al. 2012	Gleason 8-10	LC-MS/MS		1,20		0,70	2,90	1,00	1,60
	Hammond et al. 1997		Radioimmunoassay				0,69	1,03		
	Heracek et al. 2007		Radioimmunoassay	2,03	1,98	0,74				
	Hammond et al. 1978		Radioimmunoassay				1,30	3,20		
	Taplin et al. 2014		LC-MS/MS	0,98			0,09	4,47		
	Taplin et al. 2014		LC-MS/MS	1,38			0,09	7,07		
	Miyoshi et al. 2014		LC-MS/MS		1,14				1,14	1,31
Mostaghel et al. 2014		LC-MS/MS	1,17		0,47					
Røhl and Beuke 1992		Radioimmunoassay	1,20					0,99	1,40	
Hara et al. 2013		CL immunoassay	3,03		1,41					

ADT	Hammond et al. 1997	estrogens	Radioimmunoassay				0,34	0,86		
	Taplin et al. 2014		CL immunoassay	0,46			0,09	1,87		
	Mostaghel et al. 2014	ADT + bicalutamide	LC-MS/MS	0,24		0,11				
	Mostaghel et al. 2014	ADT + dutasteride	LC-MS/MS	0,14		0,12				
	Mostaghel et al. 2014	CAB	LC-MS/MS	0,12		0,07				
	Mostaghel et al. 2014	CAB + ketoconazole	LC-MS/MS	0,20		0,17				
	Røhl and Beuke 1992	orchiectomy (1m)	Radioimmunoassay	0,34					0,28	0,38
	Røhl and Beuke 1992	orchiectomy (3m)	Radioimmunoassay	0,29					0,24	0,44
	Røhl and Beuke 1992	orchiectomy (6m)	Radioimmunoassay	0,40					0,31	0,46
	Røhl and Beuke 1992	orchiectomy (12m)	Radioimmunoassay	0,37					0,29	0,60

CRPC	Hara et al. 2013		CL immunoassay	0,172		0,413				
	Kim W et al. 2014		LC-MS/MS	0,086						

Abi	Taplin et al. 2014	ADT + abiraterone (24w)	LC-MS/MS	0,210			0,086	1,053				
	Kim W et al. 2014	abiraterone + ketoconazole	LC-MS/MS	0,086								
	McKay et al. 2017	abiraterone low (+dutasteride)	LC-MS/MS		0,045						0,034	0,045
	McKay et al. 2017	abiraterone high (+dutasteride)	LC-MS/MS		0,034						0,034	0,034

Androstenedione in nmol/L												
	Paper	Comment	Modality	Mean	Median	SD	RangeL	RangeH	95%L	95%H	IQRL	IQRH
Control	Dorgan et al. 1998		Radioimmunoassay		4,75						3,92	5,68
	Chen et al. 2003		Radioimmunoassay		2,63						2,07	3,36
	Travis et al. 2007		Radioimmunoassay		4,75						3,75	5,82
	Heikkila et al. 1999		Radioimmunoassay		4,90						3,60	7,80
	Nomura et al. 1988 and Nomura et al. 1996		Radioimmunoassay		5,10						4,09	6,22
	Severi et al. 2006		Radioimmunoassay		3,60						2,76	4,58
	Tsilidis et al. 2015		Radioimmunoassay	4,72					4,60	4,84		
	Stanczyk et al. 2013		Radioimmunoassay	4,54								
	Meyer et al. 2012		Radioimmunoassay	4,54		1,40						
Hammond et al. 1978		Radioimmunoassay				1,80	2,20					

BPH	Hammond et al. 1978		Radioimmunoassay				1,50	4,50				
-----	---------------------	--	------------------	--	--	--	------	------	--	--	--	--

Prostate Cancer	Dorgan et al. 1998		Radioimmunoassay		4,78						3,77	5,87
	Chen et al. 2003		Radioimmunoassay		2,72						2,13	3,47
	Travis et al. 2007		Radioimmunoassay		4,59						3,62	5,75
	Heikkila et al. 1999		Radioimmunoassay		4,95						3,80	7,55
	Nomura et al. 1988 and Nomura et al. 1996		Radioimmunoassay		5,17						4,33	6,25
	Severi et al. 2006		Radioimmunoassay		3,63						2,61	4,51
	Hammond et al. 1978		Radioimmunoassay					1,25	3,00			
	Taplin et al. 2014	ADT group baseline	LC-MS/MS	2,67				0,09	8,87			
	Taplin et al. 2014	abiraterone group baseline	LC-MS/MS	2,07				0,86	4,65			
	Mostaghel et al. 2014		LC-MS/MS	2,97		0,97						
	Hara et al. 2013		CL immunoassay	5,58		2,13						
	Ayub and Levell 1990		Radioimmunoassay	1,59		0,26						
	Ayub and Levell 1990	orchiectomy baseline	Radioimmunoassay	1,87		0,28						

ADT	Taplin et al. 2014		LC-MS/MS	1,80			0,09	4,80		
	Mostaghel et al. 2014	ADT + bicalutamide	LC-MS/MS	3,27		2,40				
	Mostaghel et al. 2014	ADT + dutasteride	LC-MS/MS	3,70		2,84				
	Mostaghel et al. 2014	CAB	LC-MS/MS	2,33		1,18				
	Mostaghel et al. 2014	CAB + ketoconazol	LC-MS/MS	3,27		3,20				
	Hara et al. 2013		CL immunoassay	2,90		1,47				
	van der Sluis et al. 2012	orchiectomy	LC-MS/MS		2,40		0,80	8,30		
	van der Sluis et al. 2012		LC-MS/MS		2,30		0,50	7,40		
	Ayub and Levell 1990		Radioimmunoassay	1,2		0,2				
	Ayub and Levell 1990	orchiectomy	Radioimmunoassay	1,61		0,11				

CRPC	Attard et al. 2008	pre abi	LC-MS/MS		1,169		0,070	4,349		
	Ryan et al. 2014	abiraterone + prednisone (baseline)	LC-MS/MS	1,005			0,049	3,392		
	Ryan et al. 2014	prednisone (baseline)	LC-MS/MS	0,859			0,059	2,063		
	Ryan et al. 2014	prednisone (12w)	LC-MS/MS	0,859			0,059	2,063		

Abi	Taplin et al. 2014	ADT + abiraterone (24w)	LC-MS/MS	0,276			0,087	2,464		
	Attard et al. 2012		LC-MS/MS		0,011		0,003	0,055		
	McKay et al. 2017	abiraterone low (+dutasteride)	LC-MS/MS		0,017					0,010 0,017
	McKay et al. 2017	abiraterone high (+dutasteride)	LC-MS/MS		0,017					0,014 0,021
	Ryan et al. 2014	abiraterone + prednisone (12w)	LC-MS/MS	0,084		0,053				
	Attard et al. 2008		LC-MS/MS		0,070		0,070	0,070		

Estradiol levels in nmol/L												
Paper	Comment	Modality	Mean	Median	SD	RangeL	RangeH	95%L	95%H	IQRL	IQRH	

Control	Dorgan et al. 1998		Radioimmunoassay		0,103					0,081	0,125
	Chen et al. 2003		Radioimmunoassay		0,195					0,168	0,219
	Hsing and Comstock 1993 and Comstock et al. 1993		Radioimmunoassay		0,221					0,173	0,296
	Platz et al. 2005		Radioimmunoassay		0,115					0,093	0,138
	Nomura et al. 1988 and Nomura et al. 1996		Radioimmunoassay		0,066					0,051	0,084
	Severi et al. 2006		CL immunoassay		0,107					0,090	0,126
	Stattin et al. 2004	NSHDC	CL immunoassay		0,075					0,060	0,093

Control	Gann et al. 1996		Radioimmunoassay		0,125				0,099	0,154
	Barrett-Conner et al. 1990		Radioimmunoassay		0,073				0,059	0,095
	Mondul et al. 2010		CL immunoassay					0,128	0,136	
	Daniels et al. 2010		GC-MS			0,028				
	Grosman et al. 2010		Radioimmunoassay			0,056				
	Hammond et al. 1978		Radioimmunoassay				0,10	0,15		

BPH	Grosman et al. 2010		Radioimmunoassay	0,191		0,059			0,08	0,31
	Hammond et al. 1978		Radioimmunoassay				0,10	0,16		

Prostate Cancer	Dorgan et al. 1998		Radioimmunoassay		0,103					0,084	0,125
	Chen et al. 2003		Radioimmunoassay		0,191					0,165	0,215
	Hsing and Comstock 1993 and Comstock et al. 1993		Radioimmunoassay		0,233					0,178	0,301
	Platz et al. 2005		Radioimmunoassay		0,114					0,093	0,138
	Nomura et al. 1988 and Nomura et al. 1996		Radioimmunoassay		0,066					0,055	0,077
	Severi et al. 2006		CL immunoassay		0,104					0,087	0,126
	Stattin et al. 2004		CL immunoassay		0,074					0,059	0,092
	Gann et al. 1996		Radioimmunoassay		0,121					0,092	0,158
	Barrett-Conner et al. 1990		Radioimmunoassay		0,077					0,059	0,092
	Daniels et al. 2010		GC-MS	0,083		0,025					
	Grosman et al. 2010		Radioimmunoassay	0,200		0,065					
	Hammond et al. 1978		Radioimmunoassay				0,050	0,300			
	Salonia et al. 2013 (PMID: 23283410)		CL immunoassay	0,122			0,037	0,272			
	Porcaro et al. 2013		CL immunoassay	0,126		0,060					
	Porcaro et al. 2012		CL immunoassay	0,129		0,062					
	Porcaro et al. 2012		CL immunoassay	0,126		0,061					
	Salonia et al. 2012		CL immunoassay	0,121			0,022	0,327			
Salonia et al. 2013 (PMID: 22441310)		CL immunoassay	0,119			0,015	0,272				
Qin X et al. 2013		Radioimmunoassay	0,121					0,107	0,135		
Kitahara et al. 1999		Radioimmunoassay				0,004	0,114				



ADT	Basaria et al. 2002		Radioimmunoassay	0,004								
	Qin X et al. 2013	ADT responder	Radioimmunoassay	0,034					0,028	0,040		
	Qin X et al. 2013	ADT non-responder	Radioimmunoassay	0,034					0,024	0,043		
	Kitahara et al. 1999	estrogens	Radioimmunoassay				0,004	0,016				

CRPC	Qin X et al. 2013		Radioimmunoassay	0,055					0,029	0,081		
------	-------------------	--	------------------	-------	--	--	--	--	-------	-------	--	--

Androstenediol-glucoronide (AAG) levels in nmol/L												
Paper	Comment	Modality	Mean	Median	SD	RangeL	RangeH	95%L	95%H	IQRL	IQRH	

Control	Dorgan et al. 1998		Radioimmunoassay		5,7						3,9	8,5
	Chen et al. 2003		Radioimmunoassay		12,3						8,7	18,1
	Travis et al. 2007		Radioimmunoassay		13,1						9,0	19,3
	Platz et al. 2005		Radioimmunoassay		10,6						7,0	15,7
	Vatten et al. 1997		Radioimmunoassay		12,5						9,6	18,3
	Nomura et al. 1988 and Nomura et al. 1996		Radioimmunoassay		9,0						6,4	12,6
	Severi et al. 2006		Radioimmunoassay		14,3						9,8	19,8
	Gann et al. 1996		Radioimmunoassay		13,9						10,0	18,6
	Schenk et al. 2016		Radioimmunoassay	14,1					13,4	14,5		
	Tsilidis et al. 2015		Radioimmunoassay	12,9					12,3	13,5		
	Stanczyk et al. 2013		Radioimmunoassay	14,9								
	Meyer et al. 2012		Radioimmunoassay	17,5		12,1						
Wirén et al. 2007		Radioimmunoassay	13,6		8,1							

Prostate Cancer	Dorgan et al. 1998		Radioimmunoassay		6,5						3,9	8,8
	Chen et al. 2003		Radioimmunoassay		13,7						9,2	18,8
	Travis et al. 2007		Radioimmunoassay		12,7						8,6	19,2
	Platz et al. 2005		Radioimmunoassay		10,8						7,2	16,5
	Vatten et al. 1997		Radioimmunoassay		14,0						10,6	18,0
	Nomura et al. 1988 and Nomura et al. 1996		Radioimmunoassay		10,0						6,8	14,1
	Severi et al. 2006		Radioimmunoassay		13,4						9,4	18,9
	Gann et al. 1996		Radioimmunoassay		14,5						11,1	19,2

	Schenk et al. 2016		Radioimmunoassay	14,3					13,8	14,9		
	Wirén et al. 2007		Radioimmunoassay	13,6		7,0						
	Hara et al. 2013		CL immunoassay	56,2		14,7						

ADT	Hara et al. 2013		CL immunoassay	11,5		15,1						
-----	------------------	--	----------------	------	--	------	--	--	--	--	--	--

Androsterone levels in nmol/L												
Paper	Comment	Modality	Mean	Median	SD	RangeL	RangeH	95%L	95%H	IQRL	IQRH	

Con	Hammond et al. 1978		Radioimmunoassay				1	1,5				
-----	---------------------	--	------------------	--	--	--	---	-----	--	--	--	--

BPH	Hammond et al. 1978		Radioimmunoassay				0,5	2,3				
-----	---------------------	--	------------------	--	--	--	-----	-----	--	--	--	--

PC	Hammond et al. 1997		Radioimmunoassay				0,60	0,90				
	Hammond et al. 1978		Radioimmunoassay				0,50	2,20				
	Taplin et al. 2014		LC-MS/MS	0,34			0,02	1,85				
	Mostaghel et al. 2014		LC-MS/MS	0,49		0,38						

ADT	Hammond et al. 1997	estrogens	Radioimmunoassay				0,60	0,90				
	Taplin et al. 2014		LC-MS/MS	0,16			0,02	1,71				
	Mostaghel et al. 2014	ADT + bicalutamide	LC-MS/MS	0,29		0,27						
	Mostaghel et al. 2014	ADT + dutasteride	LC-MS/MS	0,20		0,20						
	Mostaghel et al. 2014	CAB	LC-MS/MS	0,23		0,21						

Abi	Taplin et al. 2014	ADT + abiraterone (24w)	LC-MS/MS	0,02			0,02	0,13				
	Kim W et al. 2014		LC-MS/MS	0,75								

Dehydroepiandrosterone (DHEA) levels in nmol/L												
	Paper	Comment	Modality	Mean	Median	SD	RangeL	RangeH	95%L	95%H	IQRL	IQRH
Con	Belanger et al. 1994		Radioimmunoassay	3,72								
	Belanger et al. 1994		Radioimmunoassay	9,52								
PC	Taplin et al. 2014		LC-MS/MS	8,38			0,09	20,57				
	Taplin et al. 2014		LC-MS/MS	6,11			1,16	15,21				
	Mostaghel et al. 2014		LC-MS/MS	12,77		5,38						
	Kitahara et al. 1999		Radioimmunoassay				1,04	2,78				
ADT	Taplin et al. 2014		LC-MS/MS	6,97			0,09	18,29				
	Mostaghel et al. 2014	ADT + bicalutamide	LC-MS/MS	15,48		9,85						
	Mostaghel et al. 2014	ADT + dutasteride	LC-MS/MS	15,48		9,85						
	Mostaghel et al. 2014	CAB	LC-MS/MS	9,44		7,11						
	Mostaghel et al. 2014	CAB + ketoconazol	LC-MS/MS	10,93		8,88						
	Kitahara et al. 1999	estrogens	Radioimmunoassay				0,69	3,12				
CRPC	Attard et al. 2008		LC-MS/MS		9,80		2,29	45,08				
Abiraterone	Attard et al. 2008		LC-MS/MS		2,748		1,398	3,598				
	McKay et al. 2017	abiraterone low (+dutasteride)	LC-MS/MS		0,066						0,062	0,094
	McKay et al. 2017	abiraterone high (+dutasteride)	LC-MS/MS		0,083						0,059	0,101
	Kim W et al. 2014	abiraterone responder	LC-MS/MS	1,492								
	Kim W et al. 2014	abiraterone non-responder	LC-MS/MS	2,464								
	Taplin et al. 2014	ADT + abiraterone (24w)	LC-MS/MS	1,031			0,087	11,257				

DHEA-sulfate (DHEAS) levels in $\mu\text{mol/L}$											
Paper	Comment	Modality	Mean	Median	SD	RangeL	RangeH	95%L	95%H	IQRL	IQRH

Control	Dorgan et al. 1998		Radioimmunoassay		3,08					2,26	4,68
	Rarter et al. 1995 and Parsons et al. 2005		Radioimmunoassay		1,24					0,84	1,95
	Chen et al. 2003		Radioimmunoassay		1,96					1,25	3,09
	Hsing and Comstock 1993 and Comstock et al. 1993		Radioimmunoassay		2,86					1,32	4,59
	Corder et al. 1995		Radioimmunoassay		2,60					1,58	3,86
	Severi et al. 2006		Radioimmunoassay		2,90					1,80	4,30
	Barrett-Conner et al. 1990		Radioimmunoassay		2,06					1,28	2,90
	Mitamura et al. 2003		LC-MS/MS	4,31			0,49	6,21			

BPH	Mitamura et al. 2003			2,60			1,27	3,71			
-----	----------------------	--	--	------	--	--	------	------	--	--	--

Prostate Cancer	Dorgan et al. 1998		Radioimmunoassay		3,28					2,34	4,95
	Rarter et al. 1995 and Parsons et al. 2005		Radioimmunoassay		1,33					0,81	1,79
	Chen et al. 2003		Radioimmunoassay		2,12					1,35	3,41
	Hsing and Comstock 1993 and Comstock et al. 1993		Radioimmunoassay		2,73					1,51	4,03
	Corder et al. 1995		Radioimmunoassay		2,84					2,03	4,12
	Severi et al. 2006		Radioimmunoassay		2,50					1,60	4,00
	Barrett-Conner et al. 1990		Radioimmunoassay		2,24					1,56	3,47
	Mitamura et al. 2003		LC-MS/MS	1,95			0,30	6,56			
	Taplin et al. 2014	ADT (baseline)	LC-MS/MS	6,25			0,66	14,07			
	Taplin et al. 2014	ADT + abiraterone (baseline)	LC-MS/MS	5,30			0,71	17,93			
	Hara et al. 2013		CL immunoassay	3,61		1,73					
	Kitahara et al. 1999		Radioimmunoassay				0,31	3,39			

ADT	Taplin et al. 2014		LC-MS/MS	5,44			0,16	14,82			
	Hara et al. 2013		LC-MS/MS	2,26		1,39					
	van der Sluis et al. 2012	orchiectomy	LC-MS/MS		1,40		0,20	7,10			
	van der Sluis et al. 2012		LC-MS/MS		1,50		0,20	4,90			
	Kitahara et al. 1999	estrogens	Radioimmunoassay				0,15	3,52			

CRPC	Matsubara et al. 2014	250 mg abiraterone baseline	LC-MS/MS		1,003		0,069	1,843		
	Matsubara et al. 2014	500 mg abiraterone baseline	LC-MS/MS		0,908		0,069	2,358		
	Matsubara et al. 2014	1000 mg abiraterone baseline	LC-MS/MS		2,507		0,243	5,068		
	Attard et al. 2008		LC-MS/MS		1,057		0,407	3,171		
	Ryan et al. 2014	abiraterone + prednisone baseline	LC-MS/MS	0,756			0,008	4,878		
	Ryan et al. 2014	prednisone baseline	LC-MS/MS	0,558			0,014	3,469		

Abi	Attard et al. 2008		LC-MS/MS		0,407		0,407	0,407		
	Ryan et al. 2014	abiraterone + prednisone (12w)	LC-MS/MS	0,144		0,086	0,003	n.d.		
	McKay et al. 2017	abiraterone low (+dutasteride)	LC-MS/MS		0,030				0,010	0,035
	McKay et al. 2017	abiraterone high (+dutasteride)	LC-MS/MS		0,017				0,010	0,032
	Taplin et al. 2014	ADT + abriaterone (24w)	LC-MS/MS	0,481			0,146	4,552		

Pregnenolone levels in nmol/L												
Paper	Comment	Modality	Mean	Median	SD	RangeL	RangeH	95%L	95%H	IQRL	IQRH	

Con	Kushnir et al. 2006		LC-MS/MS				0,88	5,21		
	Hammond et al. 1978		Radioimmunoassay				1,75	2,50		

BPH	Hammond et al. 1978		Radioimmunoassay				1,00	3,50		
-----	---------------------	--	------------------	--	--	--	------	------	--	--

PC	Hammond et al. 1997		Radioimmunoassay				1,26	1,90		
	Hammond et al. 1978		Radioimmunoassay				1,00	3,50		

ADT	Hammond et al. 1997	estrogens	Radioimmunoassay				1,26	1,90		
-----	---------------------	-----------	------------------	--	--	--	------	------	--	--

Abi	McKay et al. 2017	abiraterone + dutasteride	LC-MS/MS		16,31					9,86	27,78
-----	-------------------	---------------------------	----------	--	-------	--	--	--	--	------	-------

Progesterone levels in nmol/L												
	Paper	Comment	Modality	Mean	Median	SD	RangeL	RangeH	95%L	95%H	IQRL	IQRH

Con	Hammond et al. 1978		Radioimmunoassay				0,75	0,75				
-----	---------------------	--	------------------	--	--	--	------	------	--	--	--	--

BPH	Hammond et al. 1978		Radioimmunoassay				0,40	1,50				
-----	---------------------	--	------------------	--	--	--	------	------	--	--	--	--

PC	Hammond et al. 1978		Radioimmunoassay				0,20	1,30				
	Hammond et al. 1997		Radioimmunoassay				0,32	1,11				

ADT	Ayub and Levell 1990		Radioimmunoassay	1,82		0,26						
	Ayub and Levell 1990	orchiectomy	Radioimmunoassay	1,53		0,30						
	Hammond et al. 1997	estrogens	Radioimmunoassay				0,48	1,27				

Abi	McKay et al. 2017	abiraterone + dutasteride	LC-MS/MS		2,77						1,62	5,18
-----	-------------------	---------------------------	----------	--	------	--	--	--	--	--	------	------

17-hydroxy-pregnenolone levels in nmol/L												
	Paper	Comment	Modality	Mean	Median	SD	RangeL	RangeH	95%L	95%H	IQRL	IQRH

Con	Kushnir et al. 2006		LC-MS/MS				0,36	4,09				
-----	---------------------	--	----------	--	--	--	------	------	--	--	--	--

PC	Hammond et al. 1997		Radioimmunoassay				0,5	1,5				
	Kitahara et al. 1999		Radioimmunoassay				0,69	3,16				

ADT	Hammond et al. 1997	estrogens	Radioimmunoassay				0,5	1				
	Kitahara et al. 1999	estrogens	Radioimmunoassay				0,32	1,81				

17-hydroxy-progesterone levels in nmol/L												
	Paper	Comment	Modality	Mean	Median	SD	RangeL	RangeH	95%L	95%H	IQRL	IQRH
Con	Kushnir et al. 2006		LC-MS/MS				0,76	4,21				
	Hammond et al. 1978		Radioimmunoassay				2,75	3,00				
BPH	Hammond et al. 1978		Radioimmunoassay				2,75	7,50				
PC	Hammond et al. 1978		Radioimmunoassay				2,50	5,00				
	Ayub and Levell 1990	ADT baseline	Radioimmunoassay	1,40		0,18						
	Ayub and Levell 1990	orchiectomy baseline	Radioimmunoassay	1,58		0,12						
	Kitahara et al. 1999		Radioimmunoassay				0,61	2,42				
ADT	Kitahara et al. 1999	estrogens	Radioimmunoassay				0,30	1,82				
	Ayub and Levell 1990		Radioimmunoassay	1,14		0,16						
	Ayub and Levell 1990	orchiectomy	Radioimmunoassay	1,37		0,24						